MAPK3 and neurofibromatosis type 1: However, clinical trials with pathway inhibitors, primarily statins in NF1 patients, have had limited success, possibly due to ERK1/2-independent pathways modified in response to mutations at the level of or upstream of RAS [29,30,32,58,86,87,88,89,90].